Novartis

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novartis and other ETFs, options, and stocks.

About NVS

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. 

CEO
Vasant Narasimhan
CEOVasant Narasimhan
Employees
75,267
Employees75,267
Headquarters
Basel, Basel-Stadt (Basle Town)
HeadquartersBasel, Basel-Stadt (Basle Town)
Founded
1996
Founded1996
Employees
75,267
Employees75,267

NVS Key Statistics

Market cap
325.47B
Market cap325.47B
Price-Earnings ratio
23.99
Price-Earnings ratio23.99
Dividend yield
1.93%
Dividend yield1.93%
Average volume
1.94M
Average volume1.94M
High today
$160.93
High today$160.93
Low today
$150.06
Low today$150.06
Open price
$159.90
Open price$159.90
Volume
1.29M
Volume1.29M
52 Week high
$170.46
52 Week high$170.46
52 Week low
$121.57
52 Week low$121.57

NVS News

Nasdaq 13h
Novartis Late-Stage Cardiovascular Outcome Study Fails, Stock Down

Novartis NVS announced that the late-stage study on investigational candidate, pelacarsen, failed. Pelacarsen is an investigational antisense oligonucleotide (...

Novartis Late-Stage Cardiovascular Outcome Study Fails, Stock Down
Nasdaq 13h
Amgen Shares Fall as Novartis' Pelacarsen Misses Phase III Study Goal

Shares of Amgen AMGN were down 5% in after-hours trading on Friday after Novartis NVS announced that the phase III Lp(a)HORIZON study evaluating the latter’s in...

Amgen Shares Fall as Novartis' Pelacarsen Misses Phase III Study Goal
TipRanks 13h
Citi says Novartis news increases likelihood Crispr prioritizes next-gen CTX321

After Novartis (NVS) reported that pelacarsen’s Phase 3 HORIZON study failed to demonstrate a statistically significant reduction in major adverse cardiovascula...

Analyst ratings

41%

of 29 ratings
Buy
41.4%
Hold
41.4%
Sell
17.2%

More NVS News

TipRanks 13h
Novartis pelacarsen miss ‘not great on the margin for’ Amgen, says UBS

After Novartis (NVS) announced pelacarsen missed its primary endpoint of reducing cardiovascular events in the Phase 3 HORIZON study, UBS called the news “not g...

Investing.com 16h
Novartis shares fall after heart drug fails late-stage trial - Investing.com

...

Novartis shares fall after heart drug fails late-stage trial - Investing.com
TipRanks 19h
Novartis Pipeline Strength Outweighs Pelacarsen Setback as Sachin Jain Reiterates Buy and Raises Price Target to CHF 150

Analyst Sachin Jain from Bank of America Securities reiterated a Buy rating on Novartis AG and increased the price target to CHF150.00 from CHF140.00. Sachin Ja...

The Wall Street Journal 3d
Novartis Says Closely Watched Cholesterol Study Failed to Meet Goal

Shares of Novartis fell in after-hours trading on Friday. Florence Lo / Reuters A highly anticipated cholesterol drug from Novartis NOVN -1.33 %decrease; down...

Novartis Says Closely Watched Cholesterol Study Failed to Meet Goal
TipRanks 3d
Novartis Pelacarsen Fails to Cut Cardiovascular Events in Key Phase III Lp(a) Trial

Novartis ( (NVS) ) has provided an announcement. On September 4, 2026, Novartis reported topline Phase III results from its Lp(a)HORIZON trial evaluating pelac...

The Wall Street Journal 3d
Novartis Says Pelacarsen Heart Disease Drug Missed Primary Endpoint

Shares of Novartis declined in after-hours trading on Friday. Fabrice Coffrini / Agence France-Presse / Getty Images Novartis NOVN -1.33 %decrease; down pointi...

Novartis Says Pelacarsen Heart Disease Drug Missed Primary Endpoint
Investor's Business Daily 3d
Novartis, Ionis Tumble On Surprise Flop For Heart Drug

Technology Novartis, Ionis Tumble On Surprise Flop For Heart Drug Licensing Novartis (NVS) said late Friday its Ionis Pharmaceuticals (IONS)-partnered Lp(a) blo...

Novartis, Ionis Tumble On Surprise Flop For Heart Drug

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.